Eradication of established tumors by CD8+ T cell adoptive immunotherapy

Immunity

Volumn 13, Issue 2, 2000, Pages 265-276

  Hanson, Holly L ^a   Donermeyer, David L ^a   Ikeda, Hiroaki ^a   White, J Michael ^a   Shankaran, Vijay ^a   Old, Lloyd J ^b   Shiku, Hiroshi ^c   Schreiber, Robert D ^a   Allen, Paul M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^c MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; DOSE TIME EFFECT RELATION; DRUG MEGADOSE; FIBROSARCOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE RECEPTOR GENE;

EID: 0033680870     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-7613(00)00026-1     Document Type: Article

References (48)

1. Immunological memory and protective immunity: Understanding their relation
2. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity
3. Tumor antigens recognized by T lymphocytes
4. Tumor size at the time of adoptive transfer determines whether tumor rejection occurs
5. Severe combined immunodeficiency(SCID) in the mouse. Pathology, reconsititution, neoplasms
6. Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: Description of a unique antigen on BALB/c Meth A sarcoma
7. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
8. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro
9. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity
10. Adoptive immunotherapy prevents prostate cancer in a transgenic animal model
11. + T cells
12. TCR recognition of the Hb(64-76)/I-E(k) determinant. Single conservative amino acid changes in the complementarity-determining region 3 dramatically alter antigen fine specificity
13. An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues
14. Mutated mitogen-activated protein kinase: A tumor rejection antigen of mouse sarcoma
15. b-restricted ovalbumin peptide and an assessment of the predictive power of MHC-binding motifs
16. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo
17. TCR transgenic mice in which usage of transgenic α- and β-chains is highly dependent on the level of selecting ligand
18. Cancer statistics, 1999
19. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
20. Peptide ligand-induced conformation and surface expression of the L(d) class I MHC molecule
21. Immunotherapeutic approaches to sarcoma
22. Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors
23. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors
24. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
25. + T-cell responses and prolongs survival of thymoma-bearing mice
26. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice
27. Decreased expression of the signal-transducing ζ chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma
28. Immune surveillance against a solid tumor fails because of immunological ignorance
29. Antigenic properties of chemically-induced tumors
30. gp100/pmel 17 is a murine tumor rejection antigen: Induction of 'self'-reactive, tumoricidal T cells using high-affinity, altered peptide ligand
31. + T lymphocytes
32. Cancer vaccines
33. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo
34. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2
35. Adoptive immunotherapy of established syngeneic solid tumors: Role of T lymphoid subpopulation
36. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells
37. Molecular basis of T cell dysfunction in cancer is influenced by the paracrine secretion of tumor-derived IL-2
38. Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: Normal development but restrained effector function in vivo
39. Control of syngeneic tumor growth by activation of CD8+ T cells: Efficacy is limited by migration away from the site and induction of nonresponsiveness
40. Tumor rejection antigens of chemically induced sarcomas of inbred mice
41. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
42. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors
43. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide persentation of dendritic cells
44. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
45. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes
46. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy
47. A p161NK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma